Zacks Research Issues Pessimistic Outlook for FOLD Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities research analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Amicus Therapeutics in a note issued to investors on Tuesday, June 3rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' FY2025 earnings at ($0.01) EPS, Q2 2026 earnings at $0.04 EPS, FY2026 earnings at $0.28 EPS, Q1 2027 earnings at $0.07 EPS and FY2027 earnings at $0.43 EPS.

Several other equities analysts also recently weighed in on FOLD. UBS Group raised their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. The Goldman Sachs Group cut their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company cut their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

NASDAQ FOLD traded down $0.13 during mid-day trading on Friday, hitting $6.03. The stock had a trading volume of 4,597,797 shares, compared to its average volume of 2,948,438. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The company has a 50 day simple moving average of $6.61 and a 200 day simple moving average of $8.44. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -33.50, a P/E/G ratio of 1.51 and a beta of 0.54. Amicus Therapeutics has a 52-week low of $5.81 and a 52-week high of $12.65.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics during the 4th quarter worth $29,000. Strs Ohio bought a new position in Amicus Therapeutics during the 1st quarter worth $30,000. Covestor Ltd grew its stake in Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Amicus Therapeutics by 211.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 3,497 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Amicus Therapeutics in the 1st quarter valued at approximately $53,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.